Trials / Terminated
TerminatedNCT01990261
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated (Wild Type) Patients Treated With Erlotinib (TARceva) After the Failure of at Least One Chemotherapy Regimen
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-11-21
- Last updated
- 2016-09-16
- Results posted
- 2016-07-28
Locations
1 site across 1 country: Romania
Source: ClinicalTrials.gov record NCT01990261. Inclusion in this directory is not an endorsement.